NO20045073L - Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer - Google Patents

Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer

Info

Publication number
NO20045073L
NO20045073L NO20045073A NO20045073A NO20045073L NO 20045073 L NO20045073 L NO 20045073L NO 20045073 A NO20045073 A NO 20045073A NO 20045073 A NO20045073 A NO 20045073A NO 20045073 L NO20045073 L NO 20045073L
Authority
NO
Norway
Prior art keywords
crystals
mum
obtainable
preparation
pharmaceutical formulations
Prior art date
Application number
NO20045073A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hosel
Uwe Mueller
Annette Eichardt
Hagen Gerecke
Sabine Gliesing
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20045073L publication Critical patent/NO20045073L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet en fremgangsmåte for fremstilling av krystaller hvis gjennomsnittlige partikkelstørrelse ligger innenfor et på forhånd bestemt område mens den maksimale partikkelstørrelsen ikke overskrider en gitt verdi. Ved fremgangsmåten ifølge oppflrmelsen underkastes en overmettet oppløsning av spesielt 1 ip- benzaldoxim-estta-4,9-dien våtmaling under krystalhsasjon ved hjelp av en våtmalingsirmretning, hvorved det oppnås en primærkomsuspensjon. Det er videre beskrevet krystaller som oppnås ved frem- gangsmåten ifølge oppfmnelsen og farmasøytiske formuleringer irmeholdende nevnte krystaller.
NO20045073A 2002-04-23 2004-11-22 Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer NO20045073L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218109A DE10218109A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/005102 WO2003090714A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
NO20045073L true NO20045073L (no) 2004-11-22

Family

ID=29264788

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045073A NO20045073L (no) 2002-04-23 2004-11-22 Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer

Country Status (20)

Country Link
US (1) US7192942B2 (no)
EP (1) EP1496865B1 (no)
JP (1) JP4490114B2 (no)
KR (1) KR20040106379A (no)
CN (1) CN1646101A (no)
AT (1) ATE332686T1 (no)
AU (1) AU2003240652A1 (no)
BR (1) BR0308744A (no)
CA (1) CA2479991C (no)
DE (2) DE10218109A1 (no)
DK (1) DK1496865T3 (no)
ES (1) ES2268368T3 (no)
IL (1) IL163985A0 (no)
MX (1) MXPA04010468A (no)
NO (1) NO20045073L (no)
PL (1) PL371339A1 (no)
PT (1) PT1496865E (no)
RU (1) RU2314315C2 (no)
WO (1) WO2003090714A1 (no)
ZA (1) ZA200409395B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20090087492A1 (en) * 2006-03-14 2009-04-02 Merck & Co., Inc. Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
RU2464321C2 (ru) * 2010-12-20 2012-10-20 Федеральное государственное образовательное учреждение высшего профессионального образования "Вологодская государственная молочнохозяйственная академия им. Н.В. Верещагина" Способ производства молочного сахара
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4151219A4 (en) 2020-05-15 2024-05-15 Shionogi & Co., Ltd DRUG COMPOSITION WITH INHIBITED IMPURITIES PRODUCTION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275398B5 (de) 1988-09-07 1993-12-23 Dresden Arzneimittel Verfahren zur herstellung von feinverteilten pharmazeutischen wirkstoffen
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
KR0151363B1 (ko) * 1993-12-27 1998-10-01 시모무라 스스무 4-히드록시-4'-이소프로폭시디페닐 술폰 현상조성물, 습식분쇄방법, 및 분산액
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
AU8145198A (en) 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
CN1183102C (zh) * 1998-12-25 2005-01-05 第一精密化学株式会社 泛酸钙的制备方法
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
ATE332686T1 (de) 2006-08-15
PL371339A1 (en) 2005-06-13
DE10218109A1 (de) 2003-11-20
CA2479991A1 (en) 2003-11-06
JP2005523333A (ja) 2005-08-04
RU2314315C2 (ru) 2008-01-10
WO2003090714A1 (de) 2003-11-06
JP4490114B2 (ja) 2010-06-23
DK1496865T3 (da) 2006-10-09
US7192942B2 (en) 2007-03-20
BR0308744A (pt) 2005-01-11
RU2004134327A (ru) 2006-02-27
ZA200409395B (en) 2006-02-22
IL163985A0 (en) 2005-12-18
ES2268368T3 (es) 2007-03-16
CN1646101A (zh) 2005-07-27
AU2003240652A1 (en) 2003-11-10
CA2479991C (en) 2010-06-22
US20030225050A1 (en) 2003-12-04
EP1496865B1 (de) 2006-07-12
PT1496865E (pt) 2006-10-31
DE50304230D1 (de) 2006-08-24
EP1496865A1 (de) 2005-01-19
KR20040106379A (ko) 2004-12-17
MXPA04010468A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
DK1496865T3 (da) Fremgangsmåde til fremstilling af krystaller, ifölge denne opnåelige krystaller og deres anvendelse i farmaceutiske formuleringer
CY1106383T1 (el) Νεες διφαινζυλαζητιδινονες, η διαδικασια για την παραγωγη τους, τα φαρμακευτικα παρασκευασματα που πepιεχουν τις ενωσεις τους καθως και η χρηση τους για την αντιμετωπιση των διαταραχων μεταβολισμου λιπιδιων
NO20085078L (no) Nye forbindelser
DK297483A (da) Fremgangsmaade til fremstilling af derivater af 9-(2-hydroxyethoxymethyl)guanin
SI1358184T1 (sl) N-(3,3-dimetilindolin-6-il)(2-((4-piridilmetil)amino) (3-piridil))karboksamid in njegovi farmacevtski sestavki
DK1140945T3 (da) Kondenserede 1,2,4-thiadiazinderivater, deres fremstilling og anvendelse
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20061214L (no) 2,4-pyrimidindiaminer nyttige i behandling av neoplastiske sykdomme,r inflammatoriske forstyrrelser og immunsystemforstyrrelser
CA2290918A1 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
DK1497308T3 (da) Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer
MX2023011408A (es) Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer.
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
NO870228D0 (no) Benzimidazolderivater, fremgangsmaate til deres fremstilling og anvendelse av forbindelsene fremstilt ved fremgangsmaaten.
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer
NO20030801L (no) Aminoalkenylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte for deres fremstilling og preparater inneholdende de samme
FR2786184B1 (fr) Nouveaux derives du benzofurane, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
TR200503398T1 (tr) Trandolapril'in yeni kristal formları.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application